-transparent.png){kind=logo}
Twenty-nine acute schizophrenic patients were treated under double-blind conditions for six weeks with either centbutindole in a dose range of 3 mg/day to 4.5 mg/day or trifluoperazine in the dose range of 15 mg/day to 22.5 mg/day. Both drugs produced a significant improvement in initial psychopathology. No significant differences were demonstrated between the two treatment conditions.
Related Publications
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
January 1972,
Psychosomatics,
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
October 1983,
The Journal of the Association of Physicians of India,
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
October 1968,
Current therapeutic research, clinical and experimental,
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
March 1982,
Pharmacopsychiatria,
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
January 1971,
The Journal of clinical pharmacology and new drugs,
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
September 1974,
Current therapeutic research, clinical and experimental,
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
September 1991,
Fortschritte der Neurologie-Psychiatrie,
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
August 1974,
Current therapeutic research, clinical and experimental,
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
April 1963,
Comprehensive psychiatry,
D R Doongaji, and
R S Satoskar, and
A S Sheth, and
J S Apte, and
A B Desai, and
B R Shah
March 1969,
Diseases of the nervous system,
